Mild cognitive impairment – piracetam or vinpocetine? Reprint from: Biblioteka Medycyny Faktów 1/2013
Article Sidebar
Published:
Mar 31, 2014
Keywords:
mild cognitive impairment, dementia, vinpocetine, piracetam
Main Article Content
Abstract
Term Mild Cognitive Impairment (MCI) means memory weakness and other neurocognitive functioning with higher intensity then accounted norm of age and education level but unavailable for level of accomplished dementia’s criteria. MCI can be stable or can be converted to dementia. Currently there is no commonly accepted method of MCI treatment. In this paper short literature review about MCI treatment trials using piracetam and vinpocetine is presented.
Article Details
How to Cite
Krychowiak, G. (2014). Mild cognitive impairment – piracetam or vinpocetine?. Medycyna Faktow (J EBM), 7(1(22), 27-31. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2378
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Gabryelewicz T.: Wpływ łagodnych zaburzeń poznawczych na jakość życia osób w wieku podeszłym. W: Choroby otępienne. Teoria i praktyka. Wyd II. Leszek J. (red.). Wyd. Continuo, Wrocław 2011: 321-328.
2. Gabryelewicz T.: Łagodne zaburzenia poznawcze. Med Media, Warszawa 2003.
3. Barcikowska M.: Łagodne zaburzenia poznawcze – stan fizjologiczny czy patologiczny? Neurol. po Dyplomie 2008; 3: 27-33.
4. Pamięć i jej zaburzenia w MCI. Borkowska A. (red.). Medical Education, Warszawa 2011.
5. Gabryelewicz T., Styczynska M., Luczywek E. et al.: The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int. J. Geriatr. Psychiatry 2007; 22: 563-567.
6. Sperling R.A., Aisen P.S., Beckett L.A. et al.: Określanie przedklinicznych stadiów choroby Alzheimera: zalecenia grupy roboczej National Institute on Aging oraz Alzheimers Association. Med. Prakt. Neurologia 2011; 6(12): 9-29.
7. Sobów T.: Praktyczna psychogeriatria. Wyd. Continuo, Wrocław 2010.
8. Sobów T.: Opcje farmakoterapii zaburzeń funkcji poznawczych. Neuropsychiatria 2009; 1(3): 25-32.
9. Leczenie zespołów otępiennych. Forstl H. (red.). Wyd. Med. Urban & Partner, Wrocław 2005: 187-190.
10. Herrmann W.M. et al.: Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatiens with dementia syndrome taking piracetam. Int. Psychogeriatr. 1992; 4: 24-44.
11. Croisile B. et al.: Long-term and high-dose piracetam treatment of Alzheimers disease. Neurology 1993; 43: 301-305.
12. Waegemans T. et al.: Clinical efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis. Dement. Geriatr. Cogn. Disord. 2002; 13: 217-224.
13. Flicker L., Grimley Evans G. et al.: Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev. 2001.
14. Gabryel B., Adamek M., Pudełko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and present apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
15. Bielenberg G.: Effects of vincamine and vinpocetine on infarct size in focal cerebral ischemia. Arch. Pharmacol. 1992; 345: 122.
16. Gaal L., Molnár P.: Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Pharmacol. 1990; 187: 537-539.
17. DeNoble V.J., Repetti S.J., Gelpke L.W. et al.: Vinpocetine: Nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of step-through passive avoidance response in rats. Pharmacology Biochemistry & Behaviour 1986; 24: 1123-1128.
18. Barcikowska M., Bilikiewicz A.: Choroba Alzheimera w teorii i praktyce klinicznej. Wyd. Czelej, Lublin 2004.
19. Coleston M. et al.: Possible memory-enhancing properties of vinpocetine. Drug Dev. Res. 1988; 14: 191-195.
20. Szatmari S.Z., Whitehouse P.J. et al.: Vinpocetine for cognitive impairment and dementia. The Cochrane Database Syst. Rev. 2003(1).
21. Hindmarch I., Fuchs H.H., Erzigkeit H. et al.: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 1991; 6: 31-43.
22. Valikovics A.: Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007; 60: 301-310.
23. Valikovics A., Csányi A., Németh L.: Study of the effects of vinpocetine on cognitive functions. Ideggyogy Sz. 2011; 64: 115-120.
2. Gabryelewicz T.: Łagodne zaburzenia poznawcze. Med Media, Warszawa 2003.
3. Barcikowska M.: Łagodne zaburzenia poznawcze – stan fizjologiczny czy patologiczny? Neurol. po Dyplomie 2008; 3: 27-33.
4. Pamięć i jej zaburzenia w MCI. Borkowska A. (red.). Medical Education, Warszawa 2011.
5. Gabryelewicz T., Styczynska M., Luczywek E. et al.: The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int. J. Geriatr. Psychiatry 2007; 22: 563-567.
6. Sperling R.A., Aisen P.S., Beckett L.A. et al.: Określanie przedklinicznych stadiów choroby Alzheimera: zalecenia grupy roboczej National Institute on Aging oraz Alzheimers Association. Med. Prakt. Neurologia 2011; 6(12): 9-29.
7. Sobów T.: Praktyczna psychogeriatria. Wyd. Continuo, Wrocław 2010.
8. Sobów T.: Opcje farmakoterapii zaburzeń funkcji poznawczych. Neuropsychiatria 2009; 1(3): 25-32.
9. Leczenie zespołów otępiennych. Forstl H. (red.). Wyd. Med. Urban & Partner, Wrocław 2005: 187-190.
10. Herrmann W.M. et al.: Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatiens with dementia syndrome taking piracetam. Int. Psychogeriatr. 1992; 4: 24-44.
11. Croisile B. et al.: Long-term and high-dose piracetam treatment of Alzheimers disease. Neurology 1993; 43: 301-305.
12. Waegemans T. et al.: Clinical efficacy of Piracetam in Cognitive Impairment: A Meta-Analysis. Dement. Geriatr. Cogn. Disord. 2002; 13: 217-224.
13. Flicker L., Grimley Evans G. et al.: Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev. 2001.
14. Gabryel B., Adamek M., Pudełko A. et al.: Piracetam and vinpocetine exert cytoprotective activity and present apoptosis of astrocytes in vitro in hypoxia and reoxygenation. Neurotoxicology 2002; 23: 19-31.
15. Bielenberg G.: Effects of vincamine and vinpocetine on infarct size in focal cerebral ischemia. Arch. Pharmacol. 1992; 345: 122.
16. Gaal L., Molnár P.: Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Pharmacol. 1990; 187: 537-539.
17. DeNoble V.J., Repetti S.J., Gelpke L.W. et al.: Vinpocetine: Nootropic effects on scopolamine-induced and hypoxia-induced retrieval deficits of step-through passive avoidance response in rats. Pharmacology Biochemistry & Behaviour 1986; 24: 1123-1128.
18. Barcikowska M., Bilikiewicz A.: Choroba Alzheimera w teorii i praktyce klinicznej. Wyd. Czelej, Lublin 2004.
19. Coleston M. et al.: Possible memory-enhancing properties of vinpocetine. Drug Dev. Res. 1988; 14: 191-195.
20. Szatmari S.Z., Whitehouse P.J. et al.: Vinpocetine for cognitive impairment and dementia. The Cochrane Database Syst. Rev. 2003(1).
21. Hindmarch I., Fuchs H.H., Erzigkeit H. et al.: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int. Clin. Psychopharmacol. 1991; 6: 31-43.
22. Valikovics A.: Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 2007; 60: 301-310.
23. Valikovics A., Csányi A., Németh L.: Study of the effects of vinpocetine on cognitive functions. Ideggyogy Sz. 2011; 64: 115-120.